The study aimed to evaluate effect of rh GM-CSF on release of s ICAM-1 and SCD14 from peripheral blood mononuclear cells (PBMNCs) in culture supernatant in CLD as an indicator of their surface expression. This study was conducted on 36 patients suffering from CLD caused by schistosomiasis and / or viral hepatitis in addition to 12 healthy volunteers. PBMNCs were cultured for 36 hours without and with addition of rh GM-CSF and then levels of sICAM -1 and SCD14 were measured in culture supernatant by ELISA technique. Significant progressive increase in sICAM-1 and SCD14 levels were noted with advancement of CLD. However, significant decrease in their levels were noted in all studied groups after the addition of rh GM-CSF. It could be concluded that therapeutic trial of rh GM-CSF in CLD could be beneficial for improving monocyte count and function and decrease level of s ICAM-1 and SCD14 which are implicated in liver pathology in CLD.